SCHEMBL4365507

SCHEMBL4365507

O=C(NC(=O)N(S)c1cccc(OCCc2ccccc2)c1)c1cc2ccccc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
TSHR P16473 1/20 0.53
ALDH1A1 P00352 2/20 0.45
TP53 P04637 2/20 0.45
POLB P06746 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
SLC16A3 O15427 1/20 0.43
LMNA P02545 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
HDAC3 O15379 2/20 0.41
HDAC4 P56524 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4373593 0.81 ALDH1A1 (0.50) HPGDSMN1; SMN2TSHRALDH1A1TP53
SCHEMBL4373602 0.78 CYP1A2 (0.46) HPGDSMN1; SMN2TSHRALDH1A1LMNA
SCHEMBL4543064 0.78 SIRT2 (0.47) ALDH1A1MEN1KMT2ASIRT2MTNR1A
SCHEMBL4365503 0.78 NPC1 (0.63) HPGDSMN1; SMN2TSHRALDH1A1TP53
SCHEMBL4370528 0.77 TSHR (0.48) HPGDTSHRALDH1A1TP53POLB
SCHEMBL4375354 0.76 MAPK14 (0.49) MEN1KMT2ANPC1RAB9A
SCHEMBL2942755 0.73 MAP1LC3B (0.41) MEN1KMT2ANPC1RAB9APKM
SCHEMBL4367775 0.73 MTNR1A (0.39) HPGDALDH1A1MEN1KMT2AMAPT
SCHEMBL4999591 0.71 MTNR1A (0.55) SIRT2MTNR1AMTNR1B
SCHEMBL4993152 0.71 MTNR1A (0.55) SIRT2MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
EP-1562895-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004046095-A1 SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT HPGD 3824/4885SMN1; SMN2 2545/4885TSHR 245/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 HPGD 3743/4885SMN1; SMN2 2335/4885TSHR 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.